Our technology portfolio
Genomic and genetic testing has become a key element to drug discovery and development and is emerging in clinical routine. We are offering state of the art technologies for exploratory testing as well as for clinical decision making through Medicover Genetics
Sequencing
Next-generation sequencing
- Exome Sequencing
- Targeted NGS
- Custom Targeted NGS
- cf-DNA analysis
- RNA Exome Sequencing
- Whole Transcriptopme Analysis
- Noncoding RNA Analysis
- DNA- / RNA-methylation
- Cancer panels
- Liquid biopsy approach
Single cell sequencing
Sanger sequencing
PCR
- High-throughput RT-PCR
- Droplet Digital PCR
- Custom Droplet Digital PCR
- MSRD RT-PCR
Microarray
- comparative genomic hybridization
- Gene expression
- Genomic aberrations:
- CNV, SNPs
- DNA-methylation
NGS panels for exploratory testing
Offered by Medicover Diagnostics
Commercially available panels
- QIAGEN QIAseg Tumor Mutational Burden
- Comprehensive panel, 486 genes
- 27 MSI markers can be added
- ILLUMINA TruSight Oncology 500
- Pan-cancer panel
- 523 genes for assessment of all DNA and RNA variant types, MSI and TMB
- TWISTBIOSCIENCES Human Core Exome
- Whole exam panel (33MB)
NGS panels for clinical testing
In cooperation with our partner NIPD we are offering certain predefined NGS panels
Pre-defined panels
- Based on NIPD Genetics proven and novel technology
- Launched 2015 for cff DNA analysis (Veracity®)
- Proven clinical applicability and fidelity
- Coverage of the most clinically relevant genes
- Detection of multiple types of alterations for maximum diagnostic power
- Single nucleotide variants (SNVs)
- Insertions and deletions (INDELS)
- Translocations
- Copy number amplifications (CNAs)
- Unrivalled accuracy >99.99% with a limit of detection (LOD) down to 0.1% for SNVs/INDELS and 1% for translocations
- Superior Technology-Competitive Advantages
- Proprietary form of in-solution hybridisation technology
- Superior enrichment via custom long molecular probes (TACS)
- State of the Art error-correction method
- Novel enrichment methodology for circulating tumor DNA
- High-sensitivity INDEL detection
- Multi-engine copy number detection
- Unique Cancer-Trace-Detection technology-a prognostic factor on disease progression and outcome
NIPD PreSentia Hereditary Cancer Panel
- 18 cancer specific panels
- 1 pan cancer panel
NIPD ForeSentia Somatic Cancer Panel
- 6 cancer specific panels
- 1 pan cancer panel
- 5 therapy associated panels
Customized solutions
- Scalable Technology platform allows for rapid development of customized assays for any gene
- Technology allows development of combined assays such as Liquid Biopsy and Tissue biopsy
- Whole exome and whole genome sequencing
- Methylation analysis (epigenetics)
nipd PRE-DEFINED ngs cancer panels FOR CLINICAL TESTING
HEREDITARY CANCER PANEL
SOMATIC CANCER PANEL
Single cell sequencing
Europe-wide 10X Genomics service provider with unique on-site services – from study design to reliable data
- On-site GEM (Gel bead in Emulsion) generation and library preparation (10X Genomics Chromium Controller)
- Sequencing and the full bioinformatics pipeline
- Transformation of the data in an illustrative and understandable form
- Explore cellular heterogeneity, novel targets, and biomarkers with combined gene expression, surface protein expression, or CRISPR edits
- Analyse full length paired B-cell or T-cell receptors (V(D)J clonotypes) and antigen specificity
- Analyse chromatin accessibility for a deeper understanding of gene regulatory mechanisms
application examples
TUMOR MOLECULAR PROFILING
GENE TARGET QUANTIFICATION FOR T-CELL THERAPY
MITOCHONDRIAL SNP GENOTYPING FOR PATIENT EXCLUSION
HEREDITARY CANCER TESTING
EXOSOMAL miRNA PROFILING FOR EARLY SEPSIS DIAGNOSIS
SINGLE-CELL GENE EXPRESSION
SINGLE-CELL MULTIOMICS
TUMOR MOLECULAR PROFILING
- Identification of multiple types of somatic alterations on DNA and RNA level
- Deep sequencing, data analysis and identification of clinically actionable mutations
- RNA expression profiling
GENE TARGET QUANTIFICATION FOR T-CELL THERAPY
- Validated mRNA target quantification with short TAT
- Patient inclusion and treatment efficacy
MITOCHONDRIAL SNP GENOTYPING FOR PATIENT EXCLUSION
- Mutation profiling in mitochondria from blood
- Prevention of adverse drug effects by patient exclusion
HEREDITARY CANCER TESTING
- Identification of gremlin variants associated with increased risk for cancer (copy number variants)
- In-depth sequencing, clinical interpretation and variant classification based on established guidelines
EXOSOMAL miRNA PROFILING FOR EARLY SEPSIS DIAGNOSIS
- miRNA abundance pattern as biomarker
- Profiling across patient cohorts of different prognosis
- High-level data analysis and data integration
SINGLE-CELL GENE EXPRESSION
- Identification of different cell subtypes
- Determine the heterogeneity of the samples
- Compare the transcriptomes before and after treatment
- Characterize shifts specific for diseases and cell-surface markers
SINGLE-CELL MULTIOMICS
- Simultaneous analysis of TCR, B cell Ig, cell surface protein and gene expression, antigen specificity
- Analyse immune cell clonality and cellular context
- Identify T-cells and B-cells and V(D)J gene sequences
- Pair TCR or Ig sequences from T/B-cells
Where to find us
Our Email
Call Us
